Raised BMI is related to poorer outcomes to biologics in PsA. The mean change in outcome measures (cDAPSA, RAPID3, PsAID) was lowest among obese patients . This was observed primarily among TNFi initiators vs to OSM or IL17i @RheumNow #ACR21 Abstr#1327 https://t.co/pm7PPp9UH4 https://t.co/j5GWpCBD2d